Haisco(SZ:002653) Ge Long Hui A P P·2025-12-16 08:25Core Viewpoint - The company, Haikang (002653.SZ), announced that its subsidiary, Shanghai Haikang Shennuo Pharmaceutical Technology Co., Ltd., has received the Clinical Trial Approval Notice from the National Medical Products Administration for four new drugs, indicating progress in its drug development pipeline [1]. Group 1: Drug Approvals - The National Medical Products Administration has approved clinical trials for four drugs: HSK45019 tablets, HSK50042 tablets, injectable HSK55718, and HSK36357 capsules [1]. - The approved drugs are classified as Class 1 chemical drugs according to the regulations set forth in the announcement on chemical drug registration classification [1]. Group 2: Drug Details - HSK45019 is a tablet intended for the treatment of inflammatory bowel disease, with acceptance numbers CXHL2501072 and CXHL2501073 [2]. - HSK50042 is a tablet aimed at respiratory system diseases, with acceptance numbers CXHL2501080 and CXHL2501081 [2]. - HSK55718 is an injectable drug for acute pain, with acceptance numbers CXHL2501077 and CXHL2501078 [2]. - HSK36357 is a capsule for muscular dystrophy, with acceptance numbers CXHL2501059 and CXHL2501060 [2].